开窗医师改良支架行1区胸主动脉腔内修复术治疗主动脉弓病变的结局
本研究评估开窗医师改良支架行1区胸主动脉腔内修复术治疗主动脉弓病变的可行性与安全性。作者认为在有经验的中心,该技术可作为主动脉弓病变的替代治疗选择。
要点
- 30天估计生存率为90.9%±5.0%,30天估计免于再干预率为87.9%±5.7%。
- 中位随访48个月,估计生存率为85.1%±6.2%,估计免于再干预率为84.2%±6.5%。
核心结论
- 在有经验的中心,开窗医师改良支架行1区胸主动脉腔内修复术是治疗主动脉弓病变的替代选择。
研究设计与样本
- 2016年3月至2020年11月连续纳入34例因主动脉弓病变接受开窗医师改良支架行1区胸主动脉腔内修复术的患者。
主要发现
- 24例(70.6%)为B型主动脉夹层,9例(26.5%)为动脉瘤(其中7例位于主动脉弓小弯侧),1例(2.9%)为既往胸主动脉腔内修复术后因创伤性主动脉夹层导致的Ia型内漏。
- 所有患者近端锚定区均位于1区,除1例左锁骨下动脉外,所有主动脉弓上分支均得以重建。
- 全部病例技术成功;30天估计生存率(±标准误)为90.9%±5.0%(95%CI:77.0%-97.0%),30天估计免于再干预率(±标准误)为87.9%±5.7%(95%CI:73.4%-95.3%)。
- 中位随访48个月(范围12-68个月)期间,2例患者死亡(1例主动脉相关死亡,1例非主动脉相关死亡);1例患者在术后13个月因Ia型内漏接受再干预;所有主动脉弓上分支均通畅。
- 随访期间估计生存率(±标准误)为85.1%±6.2%(95%CI:69.9%-93.6%),1例(2.7%)患者发生卒中,估计免于再干预率(±标准误)为84.2%±6.5%(95%CI:69.9%-93.5%)。
临床怎么用
- 原文结论认为,在有经验的中心,开窗医师改良支架行1区胸主动脉腔内修复术可作为主动脉弓病变的替代治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study evaluated the feasibility and safety of zone 1 thoracic endovascular aortic repair (TEVAR) with fenestrated surgeon-modified stent-graft (SMSG) for aortic arch pathologies. METHODS: Between March 2016 and November 2020, 34 consecutive patients underwent zone 1 TEVAR with fenestrated SMSG for aortic arch pathologies. Outcomes included technical success, perioperative, and follow-up morbidity and mortality. RESULTS: During the study period, 34 patients were treated with zone 1 TEVAR with fenestrated SMSG. Twenty-four (70.6%) patients presented with type B aortic dissections, 9 (26.5%) patients presented with aneurysms (7 located on the lesser curvature side of aortic arch), 1 (2.9%) patient presented with type Ia endoleak after previous TEVAR owing to traumatic aortic dissection. The proximal landing zone for all patients were in zone 1, and all supra-aortic trunks were reconstructed, except for one left subclavian artery. Technical success was achieved in all cases. The 30-day estimated survival (±SE) was 90.9% ± 5.0% [95% confidence interval (CI): 77.0%-97.0%]. The 30-day estimated freedom from reintervention (±SE) was 87.9% ± 5.7% (95% CI: 73.4%-95.3%). At a median follow-up of 48 months (range, 12-68 months), 2 patients died, including 1 aortic-related death and 1 non-aortic-related death. One patient had reintervention 13 months after the operation owing to type Ia endoleak. All supra-aortic trunks were patent. The estimated survival (±SE) during follow-up was 85.1% ± 6.2% (95% CI: 69.9%-93.6%). One (2.7%) patient had stroke. The estimated freedom from reintervention (±SE) during follow-up was 84.2% ± 6.5% (95% CI: 69.9%-93.5%). CONCLUSIONS: Zone 1 TEVAR with fenestrated SMSG is an alternate option for treatment of aortic arch pathologies in experienced centers.
引用
- Li X, Zhang L, Song C, et al. Outcomes of Zone 1 Thoracic Endovascular Aortic Repair With Fenestrated Surgeon-Modified Stent-Graft for Aortic Arch Pathologies. J Endovasc Ther. 2022. PMID: 35786082. doi:10.1177/15266028221108903
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。